Last $0.35 USD
Change Today +0.019 / 5.74%
Volume 5.7K
CLRB On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/17/13 - $0.47
52 Week Low
11/13/13 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc. develops novel agents to detect, treat, and monitor a range of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. The company’s product candidates include positron emission tomography (PET) imaging agents, such as I-124-CLR1404, a small-molecule cancer-targeted PET imaging agent that is in Phase II trial for glioblastoma multiforme, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. It also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells, including cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a pre-clinical cancer-targeted nonradioactive chemotherapy that works primarily through Akt inhibition. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: --
Founder, Chief Scientific Officer, Director a...
Total Annual Compensation: $180.3K
Chief Financial officer, Chief Accounting Off...
Total Annual Compensation: $292.2K
Senior Vice President of Research & Developme...
Total Annual Compensation: $243.1K
Vice President of Business Development
Total Annual Compensation: $195.8K
Compensation as of Fiscal Year 2013.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Announces Transition of Simon Pedder to President and CEO

Cellectar Biosciences, Inc. announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director. Dr. Pedder was named acting chief executive officer and elected a director of Cellectar in October 2013. He has been involved in four successful new drug applications and his expertise spans many areas, including clinical development, orphan drug development, licensing and public company financing. Prior to joining Cellectar, Dr. Pedder held senior leadership positions at Hoffmann La Roche, including serving as an Officer and Vice President of Pharma Business Oncology.

Cellectar Biosciences, Inc. Announces Earnings Results for the Year Ended December 31, 2013

Cellectar Biosciences, Inc. announced earnings results for the year ended December 31, 2013. For the year, the company reported net loss attributable to common stockholders of $10.8 million or $0.19 per share compared to a net loss attributable to common stockholders of $9.3 million or $0.23 per share a year ago. Loss from operations for the year ended December 31, 2013 was $12.4 million, compared to a loss from operations of $8.75 million for the year ended December 31, 2012.

Cellectar Biosciences, Inc., Q4 2013 Earnings Call, Mar 25, 2014

Cellectar Biosciences, Inc., Q4 2013 Earnings Call, Mar 25, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $0.35 USD +0.019

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at